Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Withdrawn 3Unknown 2Recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 1Breast 1

Conditions

Ulcer 1Neoplasm Metastasis 1Melanoma 1Breast Neoplasms 1

Interventions

pembrolizumab 61Radiotherapy 55Gemcitabine 51Paclitaxel 49Cyclophosphamide 48Cisplatin 48Carboplatin 45Dexamethasone 37Bevacizumab 37Nivolumab 35Fluorouracil 34Docetaxel 34Oxaliplatin 33durvalumab 32Rituximab 28Magnetic Resonance Spectroscopy 28Leucovorin 28Drug Therapy 25Pemetrexed 24Doxorubicin 24Capecitabine 24atezolizumab 22Radiation 20Cytarabine 20Radiosurgery 19Prednisone 19Etoposide 19Irinotecan 17Bortezomib 17Cetuximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Withdrawn × Electrochemotherapy × Clear all
NCT03448666 2024-09-23

ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases

European Institute of Oncology

Phase 2 Withdrawn
Dermatologic

Melanoma

NCT01479946 2014-12-09

Electrochemotherapy For The Treatment Of Breast Cancer That Has Spread to the Skin

Uppsala University Hospital

Phase 2 Withdrawn
Breast

Breast Neoplasms

NCT00918593 2011-09-27

Palliative Treatment of Ulcerated Cutaneous Metastases: Trial Between Electrochemotherapy and Radiotherapy

Copenhagen University Hospital at Herlev

Phase 2 Withdrawn
98 enrolled

Neoplasm Metastasis, Ulcer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡